Firalis is a biotechnology company specializing in the development of biomarkers and biomarker-based diagnostic kits aimed at improving disease outcomes, patient comfort, and therapeutic decisions. Operating in the healthcare and biotechnology markets, Firalis serves a diverse range of clients including pharmaceutical companies, research institutions, and healthcare providers. The company's business model revolves around the discovery, development, and regulatory qualification of biomarkers, which are measurable indicators of biological states or conditions. These biomarkers are then integrated into diagnostic kits that can be customized to meet specific client needs. Firalis generates revenue through the sale of these diagnostic kits and by offering comprehensive biomarker services that include discovery, validation, and evaluation. The company’s expertise in biomarker activities allows for flexible stratification at both scientific and technical levels, ensuring reliable measurement of markers in biological samples. This approach not only enhances therapeutic decisions but also contributes to significant cost savings in healthcare.

Keywords: biomarkers, diagnostic kits, biotechnology, healthcare, disease outcomes, patient comfort, therapeutic decisions, regulatory qualification, customization, cost savings.